Tilray’s Aphria RX Receives Cannabis Trading License in Germany, Significantly Expanding Commercial Growth Opportunities
Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY) announced that its subsidiary Aphria RX GmbH has received a trading license in Germany. This license allows Aphria RX to sell and distribute a wide range of medical cannabis products to pharmacies, hospitals, and medical wholesalers throughout Germany. The development significantly expands Tilray's commercial growth opportunities in the German market.
With both cannabis cultivation and trade licenses, Tilray is now well-positioned to capitalize on the growing market opportunity in Germany. This further strengthens Tilray's position as a global leader in cannabis research, cultivation, production, and distribution. The company remains committed to advocating for responsible cannabis regulations, education, research, and accessibility to high-quality medical cannabis.
Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY) ha annunciato che la sua controllata Aphria RX GmbH ha ricevuto una licenza di commercio in Germania. Questa licenza consente ad Aphria RX di vendere e distribuire un'ampia gamma di prodotti di cannabis medicinale a farmacie, ospedali e grossisti medici in tutta la Germania. Lo sviluppo amplia significativamente le opportunità di crescita commerciale di Tilray nel mercato tedesco.
Con entrambe le licenze per la coltivazione e il commercio della cannabis, Tilray è ora ben posizionata per sfruttare l'opportunità di mercato in crescita in Germania. Questo rafforza ulteriormente la posizione di Tilray come leader globale nella ricerca, coltivazione, produzione e distribuzione della cannabis. L'azienda rimane impegnata a sostenere regolamenti responsabili sulla cannabis, educazione, ricerca e accesso a cannabis medicinale di alta qualità.
Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY) anunció que su subsidiaria Aphria RX GmbH ha recibido una licencia de comercio en Alemania. Esta licencia permite a Aphria RX vender y distribuir una amplia gama de productos de cannabis medicinal a farmacias, hospitales y mayoristas médicos en toda Alemania. Este desarrollo amplía significativamente las oportunidades de crecimiento comercial de Tilray en el mercado alemán.
Con licencias tanto para el cultivo como para el comercio de cannabis, Tilray está ahora bien posicionada para capitalizar la creciente oportunidad de mercado en Alemania. Esto fortalece aún más la posición de Tilray como líder global en investigación, cultivo, producción y distribución de cannabis. La compañía sigue comprometida a abogar por regulaciones responsables sobre cannabis, educación, investigación y acceso a cannabis medicinal de alta calidad.
Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY)는 그 자회사인 Aphria RX GmbH가 독일에서 상장 라이센스를 받았다고 발표했습니다. 이 라이센스는 Aphria RX가 전국의 약국, 병원 및 의료 도매업체에 다양한 의료용 대마초 제품을 판매 및 배급하는 것을 허용합니다. 이 발전은 Tilray의 독일 시장에서의 상업적 성장 기회를 크게 확대합니다.
대마초 재배 및 거래 라이센스를 모두 보유하게 되면서, Tilray는 이제 독일에서 성장하는 시장 기회를 활용할 수 있는 좋은 위치에 있습니다. 이는 Tilray가 대마초 연구, 재배, 생산 및 유통의 글로벌 리더로서의 위치를 더욱 강화합니다. 이 회사는 책임 있는 대마초 규제, 교육, 연구 및 고품질 의료용 대마초에 대한 접근을 옹호하는 데 전념하고 있습니다.
Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY) a annoncé que sa filiale Aphria RX GmbH a reçu une licence de commerce en Allemagne. Cette licence permet à Aphria RX de vendre et distribuer une large gamme de produits de cannabis médical aux pharmacies, hôpitaux et grossistes médicaux dans toute l'Allemagne. Ce développement élargit considérablement les opportunités de croissance commerciale de Tilray sur le marché allemand.
Avec des licences pour la culture et le commerce du cannabis, Tilray est désormais bien positionnée pour capitaliser sur les opportunités croissantes du marché en Allemagne. Cela renforce encore la position de Tilray en tant que leader mondial de la recherche, de la culture, de la production et de la distribution de cannabis. L'entreprise reste engagée à plaider pour des réglementations responsables sur le cannabis, l'éducation, la recherche et l'accès à un cannabis médical de haute qualité.
Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY) gab bekannt, dass ihre Tochtergesellschaft Aphria RX GmbH eine Handelslizenz in Deutschland erhalten hat. Diese Lizenz erlaubt es Aphria RX, ein breites Spektrum an medizinischen Cannabisprodukten an Apotheken, Krankenhäuser und medizinische Großhändler in ganz Deutschland zu verkaufen und zu vertreiben. Diese Entwicklung erweitert erheblich die kommerziellen Wachstumsmöglichkeiten von Tilray im deutschen Markt.
Mit sowohl Anbau- als auch Handelslizenzen ist Tilray nun gut positioniert, um von der wachsenden Marktchance in Deutschland zu profitieren. Dies stärkt Tilrays Position als weltweit führendes Unternehmen in der Cannabisforschung, -anbau, -produktion und -verteilung. Das Unternehmen bleibt engagiert, sich für verantwortungsvolle Cannabisregulierungen, Bildung, Forschung und den Zugang zu hochwertigem medizinischen Cannabis einzusetzen.
- Aphria RX obtained a trading license in Germany, allowing for broader distribution of medical cannabis products
- Tilray now holds both cultivation and trading licenses in Germany, strengthening its market position
- Expanded commercial growth opportunities in the German medical cannabis market
- None.
Insights
Tilray's acquisition of a trading license for Aphria RX in Germany marks a significant milestone in the company's European expansion strategy. This development positions Tilray to capitalize on Germany's growing medical cannabis market, which is projected to reach
The dual possession of cultivation and trading licenses gives Tilray a competitive edge in the German market. It allows for vertical integration, potentially leading to improved profit margins and greater control over the supply chain. This could translate to more consistent product quality and supply for patients, a important factor in the medical cannabis industry.
However, investors should note that the German medical cannabis market is still in its infancy and faces regulatory challenges. The success of Tilray's expansion will depend on factors such as:
- The pace of regulatory reforms in Germany
- The company's ability to navigate complex healthcare systems
- Competition from both domestic and international players
While this news is undoubtedly positive for Tilray, it's important to consider the broader context of the global cannabis industry, which has faced headwinds in recent years. Tilray's success in Germany will be important for its overall growth strategy and could serve as a blueprint for expansion into other European markets.
The acquisition of a trading license in Germany represents a significant growth opportunity for Tilray. Germany, with its population of over 83 million and robust healthcare system, is poised to become Europe's largest medical cannabis market. This move could potentially boost Tilray's revenue and market share in the coming years.
From a financial perspective, this development is promising for several reasons:
- Expanded market access: The ability to sell directly to pharmacies, hospitals and wholesalers could lead to increased sales volume and potentially higher margins.
- Diversification: This strengthens Tilray's international presence, reducing reliance on any single market.
- First-mover advantage: Being among the early entrants with both cultivation and trading licenses could help Tilray establish brand loyalty and capture market share.
However, investors should be cautious. The impact on Tilray's financials may not be immediate, as building a presence in a new market takes time and investment. Additionally, operating in multiple international markets increases complexity and potential regulatory risks.
While this news is positive, it's important to monitor Tilray's execution in the German market and its ability to translate this opportunity into tangible financial results in the coming quarters.
The granting of a trading license to Tilray's Aphria RX in Germany signifies a pivotal shift in the country's approach to medical cannabis. This development aligns with the broader trend of European countries reassessing their cannabis policies, potentially paving the way for more comprehensive reforms.
From a policy perspective, this move by Germany carries several implications:
- Patient access: Increased distribution channels could improve availability and potentially reduce costs for patients, addressing a key healthcare policy goal.
- Quality control: By allowing established international players like Tilray to operate, Germany can leverage global best practices in cultivation and distribution.
- Economic impact: The expansion of the medical cannabis industry could create jobs and generate tax revenue, aligning with economic policy objectives.
However, challenges remain. The medical cannabis landscape in Germany is still evolving and policymakers will need to address issues such as:
- Standardization of prescribing practices
- Integration with existing healthcare systems
- Balancing patient needs with concerns about potential misuse
Tilray's expanded presence in Germany could influence these policy discussions. As a major industry player, the company may have opportunities to shape regulations and standards, potentially benefiting both patients and the broader industry.
This development underscores the importance of continued dialogue between industry, policymakers and healthcare professionals to ensure that the growth of the medical cannabis sector aligns with public health objectives.
NEUMÜNSTER, Germany, July 29, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a global leader in medical cannabis research, cultivation, production, and distribution, today announced that Aphria RX GmbH (“Aphria RX”) has received a trading license, which will allow it to sell and distribute a broad range of medical cannabis products to pharmacies, hospitals, and medical wholesalers throughout Germany.
"This milestone of Aphria RX obtaining both its new cultivation license as well as its trading license further expands Tilray's leadership in medical cannabis research, cultivation, production and distribution in Germany and once again proves our commitment to be one of the most responsible, trusted and market leading cannabis companies in the world with a portfolio of innovative and high-quality products that address the needs of patients. We remain dedicated to advocating for responsible cannabis regulations, education and research and accessibility to high-quality medical cannabis," said Denise Faltischek, Chief Strategy Officer and Head of International at Tilray.
With both cannabis cultivation and trade licenses, Tilray is now in a strong position to fully leverage the growing market opportunity in Germany, further expanding Tilray's position as a global leader in cannabis research, cultivation, production, and distribution.
As a leading and trusted medical cannabis company, Tilray strongly believes that these developments will have a positive impact on the health and wellbeing of patients in Germany. Tilray is committed to working with the German government and all stakeholders to promote improved access to medical cannabis, optimize care for patients, and advance the science of cannabis.
About Tilray Medical
Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray, Aphria, Broken Coast, Symbios, and Navcora. Tilray Medical grew from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first GMP-certified cannabis production facilities in Portugal and Germany. Today, Tilray Medical is one of the biggest suppliers of medical cannabis brands to patients, physicians, hospitals, pharmacies, researchers, and governments, in over 20 countries and across five continents.
Further information can also be found at www.tilraymedical.de
About Tilray Brands
Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global cannabis lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is changing people's lives for the better – one person at a time – by inspiring and empowering a worldwide community to live their very best life, enhanced by moments of connection and wellbeing. Tilray’s mission is to be the most responsible, trusted and market leading cannabis consumer products company in the world with a portfolio of innovative, high-quality, and beloved brands that address the needs of the consumers, customers, and patients we serve. A pioneer in cannabis research, cultivation, and distribution, Tilray’s unprecedented production platform supports over 20 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages.
For more information on how we open a world of wellbeing, visit, Tilray.com and follow @Tilray on all social platforms.
Forward-Looking Statements
Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company’s ability to commercialize new and innovative products worldwide. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws.
For further information:
Media: news@tilray.com
Investor Relations: investors@tilray.com
FAQ
What new license did Tilray's subsidiary Aphria RX receive in Germany?
How does the new trading license benefit Tilray (TLRY) in the German market?
What types of licenses does Tilray (TLRY) now hold in Germany?
What is Tilray's (TLRY) commitment regarding medical cannabis in Germany?
